Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jul 17;11:1758835919853196. doi: 10.1177/1758835919853196

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2019

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 3. — Kaplan–Meier analysis, comparison of second-line cohorts nal-IRI plus 5-FU/LV and oxaliplatin plus fluoropyrimidines.

Progression-free survival and overall survival of patients who were treated with nal-IRI plus 5-FU/LV versus oxaliplatin plus fluoropyrimidines as second-line treatment after previous gemcitabine-based chemotherapy (A, B), with disease control in the first-line treatment versus with progressive disease (C, D) and with CA 19- 9 levels ⩾ median at start of second-line treatment (E, F).

nal-IRI, nanoliposomal irinotecan; 5-FU/LV, 5-fluorouracil/leucovorin.